Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.
Kim A PappM G LebwohlLluis L PuigM OhtsukiS BeissertJ ZengS RubantR SinvhalY ZhaoA M SolimanG AlperovichC LeonardiPublished in: The British journal of dermatology (2021)
Overall, long-term continuous RZB was well tolerated and showed high and durable efficacy over 172 weeks.